King's College London

Psilocybin in Functional Neurological Disorder (PsiFUND)

Start Date

January 1, 2024

Compounds

Psilocybin

Psilocybin in Adults With and Without Autism Spectrum Disorder (PSILAUT)

Start Date

December 1, 2022

Compounds

Psilocybin, Placebo

Synaptic Imaging and Network Activity in Treatment Resistant Depression (SIGNATURE)

Start Date

October 20, 2021

Compounds

Ketamine, Placebo

Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine

Start Date

September 27, 2021

Compounds

Ketamine, Placebo

A randomised, placebo controlled trial of psilocybin in treatment resistant depression: A feasibility study

Start Date

May 22, 2020

Compounds

Psilocybin, Placebo

Ketamine’s Actions on Rumination Mechanisms as an Antidepressant

Start Date

January 9, 2014

Compounds

Ketamine, Placebo

The combination of exercise and psychedelics for the treatment of major depressive disorder

This commentary (2026) proposes that exercise and psychedelics may complement each other as treatments for major depressive disorder through several biological mechanisms (e.g., synergistic effects on BDNF, neuroplasticity, glutamate, and serotonin) as well as psychological mechanisms (e.g., psychedelics facilitating exercise habit adoption and exercise), potentially enabling deeper psychedelic experiences.

Published

March 7, 2026

Journal

Discover Mental Health

Authors

Fabiano, N., Stubbs, B., Lawrence, D. W., Rosenblat, J. D., Teixeira, P. J., Wong, S., Zhou, C., Carhart-Harris, R. L.